Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications; headwinds remain

October 27, 2017 7:57am

What I see written about more frequently are indications of ETF exposure

As a number of technical indicators are weak or continue flashing warning signals

Yet, I am still of the opinion that many sector companies are oversold which says there will be a rebound but, how soon?

No subscription - you’re missing situational awareness!

Pre-open indications: 1 SELL and 3 BUYs

For continued access to what one industry CEO calls the “bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below: http://www.regmedinvestors.com/create-account

What’s the gauge of pricing expectation – monetization of information!

Higher open expected

Dow futures are UP +0.18% (41 points) and NASDAQ futures are 0.51% (30.7 points)

U.S. stock index futures pointed to a higher open Friday after the release of stronger-than-expected earnings from large-cap tech companies.

European stocks were higher, supported by upbeat earnings and the prospect of continuing stimulus in Europe.

Asian indexes closed higher as the euro extended losses after Thursday news from the European Central Bank following U.S. stocks closing mostly higher and then several big name tech companies reporting expectation-topping results.

Issues that will affect the trading day: corporate earnings continue

Data docket: real gross domestic product (GDP) data is expected to keep investors buzzing on Wall Street, with the latest economic data set to be published at 8:30 a.m. ET. Elsewhere, consumer sentiment data is expected to be released around 10 a.m. ET.

The cell therapy sector closed NEGATIVE on Thursday, Wednesday, Tuesday and Monday and POSITIVE last Friday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

· Thursday closed NEGATIVE with 27 decliners, 10 advancers and 6 flat;

· Wednesday closed NEGATIVE with 30 decliners, 11 advancers and 2 flats;

· Tuesday closed NEGATIVE with 28 decliners, 10 advancers and 5 flats;

· Monday closed NEGATIVE with 24 decliners, 15 advancers and 4 flats;

· Last Friday closed POSITIVE with 11 decliners, 28 advancers and 4 flats;

Henry’omics:

From Thursday night’s closing bell post, “investors abandon the sector as depreciation takes its toll; managements had better start recognizing investor loyalty as an asset versus a commodity to be discounted.”

The buying appetite is more than way off the mark as NO news of value means plummeting share pricing.

TGIF ... the volatility has knocked me over - not down but, too many times; while I stay an OPTIMIST ... re share and sector pricing with a spurt post Q3 results!

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?

Watch list:

The iShares Nasdaq Biotechnology (IBB) is indicating a POSITIVE +0.16% in Friday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is NOT indicating in Friday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Friday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.34% in Friday’s pre-open

Companies in my headlights:

Cellectis SA (CLLS) closed down -$0.22 to $32.08 after Wednesday’s +$0.56 to $32.50 with 447.1 K shares traded after Tuesday’s +$0.97 to $31.94 with 354.6 K shares traded after Monday’s +$0.58 or +1.91% to $30.97 with 335.5 k shares traded <3 month average = 206.6 K shares>. The aftermarket indication is a NEGATIVE -$0.26 or -0.82% – my “gut” says Maintaining SELL;

Pluristem (PSTI) closed down again -$0.06 to $1.92 after Wednesday’s -$0.02 to $1.98. A rebound after news of PSTI receiving approval from Israel’s Ministry of Health and the U.S. FDA to initiate a PI trial studying the company’s PLX-R18 cell therapy as a treatment for insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT). The pre-open indication is a POSITIVE +$0.05 or +2.53% - Maintaining BUY;

Regenxbio (RGNX) closed down -$2.60 to $28.50 with 471.1 K share traded after Wednesday’s +$0.60 to $31.10 with 194.2 K shares traded after Tuesday’s -$0.60 to $30.50 with 333.6 K shares traded <3 month average = 321.8 shares> after Monday’s -$1.65 ($31.10) after being up on Friday +$0.30 ($32.75). October started at $33.50 with a high of $33.65 and a low of $30.50. I’ve been a fan as RGNX usually recoups its losses – Maintaining BUY;

Sangamo Therapeutics (SGMO) closed down -$0.57 to $12.025 with 2 M shares traded after Wednesday’s -$0.75 to $12.60 with 1.57 M shares traded <3 month average = 1.65 M shares>. SGMO has been taking some serious hits since 10/3’s $17.00 and 10/3’s $16.20. An aftermarket indication is an upside +$0.58 or +4.78% - Oversold BUY;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 53 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.